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Abstract  
Background: Antibiotic resistance has been increasingly reported in decompensated cirrhosis in 
single-center studies. Prospective investigations reporting broad epidemiological data are scarce. 
Aims and Methods: Prospective evaluation in 2 series of patients hospitalized with 
decompensated cirrhosis. The Canonic series included 1146 patients from Northern, Southern 
and Western Europe in 2011. Data on epidemiology, clinical characteristics of bacterial infections, 
microbiology and empirical antibiotic schedules were assessed. A second series of 883 patients 
from Eastern, Southern and Western Europe was investigated to evaluate potential 
epidemiological changes (2017-2018). 
Results: 455 patients developed 520 infections (39.7%) in the first series. Spontaneous bacterial 
peritonitis, urinary tract infections and pneumonia were the most frequent infections. Nosocomial 
episodes predominated in this series. Nearly half of the infections were culture-positive; 29.2% of 
them were caused by multidrug-resistant organisms (MDROs). MDR strains were more frequently 
isolated in Northern and Western Europe. ESBL-producing Enterobacteriaceae were the most 
frequent MDROs isolated in this series although prevalence and type of MDROs differed 
markedly among countries and centers. Antibiotic resistance was associated to poor prognosis 
and to failure of antibiotic strategies based on third-generation cephalosporins or quinolones. 
Nosocomial infection (OR: 2.74; p<0.001), ICU admission (OR: 2.09; p=0.02), and recent 
hospitalization (OR: 1.93; p=0.04) were identified as independent predictors of MDR infection. 
Prevalence of MDROs in the second series (392 infections/284 patients) was 23%; 38% in 
culture-positive infections. A mild increase in the rate of carbapenem-resistant 
Enterobacteriaceae was observed in this series. 
Conclusions: MDR bacterial infections constitute a prevalent, growing and complex healthcare 
problem in decompensated cirrhosis and ACLF across all Europe and negatively impact 
  
prognosis. Strategies aimed at preventing the spread of antibiotic resistance in cirrhosis should be 
urgently evaluated. 
  
 
LAY SUMMARY 
Infections caused by bacteria resistant to the main antibiotic families are prevalent in patients with 
cirrhosis. This study demonstrates that this healthcare problem is increasing and extends through 
all European regions. Infections caused by these difficult to treat bacteria solve less frequently 
and often cause the death of the patient. Type of resistant bacteria varies markedly among 
different hospitals.  
INTRODUCTION 
Bacterial infections constitute a frequent complication of patients with decompensated cirrhosis 
and the most frequent trigger of ACLF in Western countries.1-5 Patients with cirrhosis and acute 
decompensation (AD) are prone to develop spontaneous and secondary bacterial infections, risk 
that magnifies at short-term in patients with ACLF.1,5,6 Bacterial infection has a critical relevance 
in the clinical course of decompensated cirrhosis, increasing 2-4 fold short-term mortality.7,8 
Recent data also show that bacterial infections are severe and associated with intense systemic 
inflammation, poor clinical course and high mortality in patients with ACLF.6 
Early diagnosis and adequate empirical antibiotic therapy of bacterial infections is key in the 
management of cirrhotic patients.1,9 However, epidemiology of bacterial infections is nowadays 
much more complex than in the past.9 The efficacy of classical empirical antibiotic strategies 
based on the administration of third-generation cephalosporins has markedly decreased in the 
last decade due to the emergence of multidrug-resistant (MDR) bacteria.9-13 Resistance to 
antibiotics in pathogenic bacteria is currently a major global public health problem,14 and is 
particularly serious in patients with decompensated cirrhosis. These patients frequently 
accumulate several risk factors for MDR organisms (MDROs) including recurrent hospitalizations, 
invasive procedures and repeated exposures to prophylactic or therapeutic antibiotics.9 Antibiotic 
overuse and failure of control measures to prevent the spread of MDROs in the healthcare setting 
have magnified antimicrobial resistance in cirrhosis. Therefore, the characterization of these 
  
epidemiological changes and the identification of the MDROs that infect our cirrhotic patients are 
of major clinical relevance. The great majority of the epidemiological data on antibiotic resistance 
in cirrhosis derive from single-centre studies2,4,10-13,15-20 or from multicentre studies performed in 
specific countries21 or assessing specific infections.22 However, at present no study has been 
reported in patients with cirrhosis and all type of infections, exploring the epidemiology of MDROs 
in large geographical, multinational regions. These studies are essential to understand the global 
impact of antibiotic resistance. 
Therefore, the current study was designed to assess the prevalence of MDR bacterial infections 
in cirrhosis across Europe, potential epidemiological differences among regions and centers, the 
characteristics of these infections, their impact on prognosis, risk factors for MDR and type and 
efficacy of empirical antibiotic treatment using information carefully collected on bacterial infection 
from the Canonic Study database.5 Additionally we analyzed a more recent series to detect new 
potential epidemiological changes. 
 
  
 
PATIENTS AND METHODS 
Study population and aims of the study 
In the current investigation two prospective series were evaluated. The first one considered all 
patients included in the Canonic series (February to September 2011). Fifty-three subjects with 
and 150 without infection with incomplete data at inclusion or during follow-up were excluded. 
Therefore, 1146 patients were analyzed, 375 with ACLF (269 diagnosed at enrolment and 106 
during hospitalization) and 771 with AD. Data on epidemiology, clinical characteristics of 
infections, microbiology and empirical and final antibiotic schedules were prospectively recorded. 
A more recent series was also evaluated to assess new potential epidemiological changes (April 
2017 to February 2018). It was extracted from a currently ongoing prospective study on the 
natural history of decompensated cirrhosis. Patients who completed the 12 weeks follow-up were 
included (883 patients out of 1295). 
The aim of the study was to assess the epidemiology of bacterial infections across Europe and 
potential differences in the prevalence and type of MDROs among geographical areas, countries 
and centers. Three different strategies for the analysis of the data were used. First, infections 
developing in the whole region and in the different European regions as defined by the United 
Nations Geoscheme for Europe were compared. In Canonic series the regions and countries 
included were the following: Northern Europe (Denmark, Ireland, UK), Western Europe (Austria, 
Belgium, France, Germany, Netherlands and Switzerland) and Southern Europe (Italy and 
Spain). Infections occurring in Czech Republic were not considered in this analysis (n=3; Eastern 
Europe). The second series included infections developed in Western (Belgium, France, 
Germany, Netherlands and Switzerland), Southern (Italy and Spain) and Eastern Europe 
(Hungary, Slovakia). Second, comparisons were performed among countries (11 in the first series 
and 9 in the second) and centers (27 in the Canonic series and 19 in the second series). Finally, 
the third objective was to perform a comprehensive assessment of the impact and risk factors of 
  
MDR bacterial infections and to evaluate the type and efficacy of empirical antibiotic strategies 
used in the whole region. This last objective was only evaluated in the Canonic series. 
 
Definitions on bacterial infection and ACLF 
Diagnostic criteria of bacterial infections were the following: spontaneous bacterial peritonitis 
(SBP): polymorphonuclear (PMN) cell count in ascitic fluid ≥250/mm3; urinary tract infection 
(UTI): abnormal urinary sediment (>10 leukocytes/field) and positive urinary culture or 
uncountable leukocytes per field if negative cultures; spontaneous bacteremia: positive blood 
cultures and no cause of bacteremia; secondary bacteremia: a) catheter-related infection 
(positive blood and catheter cultures), b) bacteremia occurring within 24h after an invasive 
procedure; pneumonia: clinical signs of infection and new infiltrates on chest x-ray; bronchitis: 
clinical features of infection, no radiographic infiltrates and positive sputum culture; skin and soft 
tissue infections (SSTI): clinical signs of infection associated with swelling, erythema, heat and 
tenderness in the skin; cholangitis: cholestasis, right upper quadrant pain and/or jaundice and 
radiological data of biliary obstruction; spontaneous bacterial empyema (SBE): PMN count in 
pleural fluid ≥500/mm³ (250/mm³ if positive culture) ; secondary peritonitis: PMN count in ascitic 
fluid ≥250/mm³ and evidence (abdominal CT/ surgery) of an intraabdominal source of infection; 
Clostridium difficile infection (CDI): positive stool toxin in a patient with diarrhea; unproved 
bacterial infection: presence of fever (≥ 38ºC) and leukocytosis (white blood cell count ≥ 12.000 
/mm3) requiring antibiotic therapy without any identifiable source. Infections diagnosed at 
admission or within 2 days after admission were classified as healthcare-associated (HCA) in 
patients with a prior contact with the healthcare environment (hospitalization or short term-
admission for at least 2 days in the previous 90 days, residence in a nursing home or a long-term 
care facility or chronic hemodialysis). The remaining infections were considered community-
  
acquired when they were present at admission or developed within the first 48 hours after 
hospitalization and nosocomial when the diagnosis was made thereafter.6,10 
MDR was defined as acquired non-susceptibility to at least one agent in three or more 
antimicrobial categories. Extensively-drug resistance (XDR) was defined as non-susceptibility to 
at least one agent in all but two or fewer antimicrobial categories and pandrug-resistant (PDR) as 
non-susceptibility to all currently available agents.23 The following bacteria were considered MDR 
in the current study: extended-spectrum beta-lactamase (ESBL, mainly Escherichia coli and 
Klebsiella pneumoniae) or desrepressed chromosomic AmpC ß-lactamase-producing 
Enterobacteriaceae (Enterobacter or Citrobacter spp), carbapenem-resistant Klebsiella 
pneumoniae, carbapenem-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia, 
carbapenem-resistant Acinetobacter baumanii, Burkholderia cepacia, methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-susceptible and vancomycin-resistant 
Enterococcus faecium (VSE, VRE). 
ACLF at infection diagnosis was defined according to the CLIF consortium criteria.5 Patients were 
considered to have SIRS (sepsis) if they fulfilled at least two of the following criteria: (a) core 
temperature > 38ºC or < 36ºC; (b) heart rate > 90 beats/minute; (c) respiratory rate > 20 
breaths/minute in the absence of hepatic encephalopathy; and (d) white blood cell count > 12.000 
or < 4000 /mm3, or differential count showing ≥ 10% immature PMN neutrophils. Severe sepsis 
was defined by the presence of SIRS and at least one acute organ failure. Septic shock was 
diagnosed by the presence of data compatible with SIRS and need of vasopressor drugs in the 
setting of hypotension.24 Recently defined sepsis criteria were not applied in the current study as 
they were proposed after the end of the Canonic Study.25 
Infections were considered cured when all clinical signs of infection disappeared and on the 
presence of: a) urinary infections: normal urine sediment and negative urine culture; b) 
spontaneous or secondary bacteremia: negative control cultures after antibiotic treatment; c) 
  
pneumonia: normal chest X-ray and negative control cultures if positive at diagnosis; d) 
bronchitis: negative bronchial aspirate/sputum culture; e) cellulitis: normal physical exam of the 
skin and negative control cultures if positive at diagnosis; f) cholangitis: improvement of 
cholestasis, resolution of clinical symptoms and negative control cultures if positive at diagnosis; 
g) SBP and SBE: PMN cell count in ascitic/pleural fluid < 250/mm³ and negative control cultures if 
positive at diagnosis. Resolution of the rest of infections was based on conventional clinical 
criteria. 
 
Definitions on antibiotic therapy in the Canonic series 
Two types of empirical antibiotic strategies were considered: 1) “Classical” strategies: those 
including first to third-generation cephalosporins, amoxicillin clavulanic-acid/cloxacillin or 
quinolones and 2) MDR strategies: regimens using piperacillin-tazobactam, carbapenems or 
ceftazidime/cefepime± glycopeptides (or linezolid/daptomycin).  
The criteria used to consider an initial antibiotic therapy appropriate were the following: 1) Culture 
positive infections: if an antibiotic with an in vitro activity appropriate for the isolated pathogen or 
pathogens was administered at diagnosis of infection; 2) Culture-negative infections: when the 
antibiotic strategies administered at the time of infection diagnosis solved the infection without 
need for further escalation. Otherwise, the initial therapy was considered inappropriate.6 
Fulfillment of international guidelines1 was not used as criterion because there were no broadly 
accepted norms for empiric management of bacterial infections in cirrhosis at the time of 
performing the study. Time to antibiotic therapy administration after diagnosis of infection was not 
recorded. 
 
Statistical analysis  
Results are presented as frequencies and percentages for categorical variables, means and SDs 
for normally distributed continuous variables and median and interquartile range for not normally 
  
distributed continuous variables. In univariate analyses, Chi-square test was used for categorical 
variables, Student’s t-test or ANOVA for normal continuous variables and Mann-Whitney or 
Kruskal Wallis test for not normally distributed continuous variables. To identify predictors of 
infection caused by MDROs, logistic regression models were carried out. Factors showing a 
clinically and statistically significant association to the outcome in univariate analyses (p<0.1) 
were selected for the initial model. The final models were fitted by using a step-wise forward 
method based on Likelihood Ratios with the same significance level (p<0.05) for entering and 
dropping variables. Binary logistic regression models were used to identify independent 
predictors of MDROs. In all statistical analyses, significance was set at p<0.05. Analyses were 
done with SPSS (version 23.0; SPSS, Inc. Chicago, IL) and SAS (version 9.4; SAS Institute Inc.; 
Cary, NC) statistical packages. 
  
RESULTS 
CANONIC SERIES  
Overall bacterial infections 
Table 1 shows the prevalence, type, clinical and epidemiological characteristics of bacterial 
infections diagnosed in the whole Canonic series and in patients from Northern, Southern and 
Western Europe. A total of 455 patients (39.7%) developed 520 bacterial infections during the 
study period with no differences in the prevalence of infection between European regions. Fifty-
eight patients developed 2 or more infections. The majority of infections were diagnosed outside 
the ICU (81.8%). Regular ward was the most frequent site of hospitalization at infection diagnosis 
in Northern and Western Europe (49% and 42.5%, respectively) and emergency department 
(64%) in Southern Europe (p<0.001). SBP (n=130) and UTI (n=111) were the most frequent 
proved infections in the whole series and in patients from Southern and Western Europe. 
Pneumonia was the most prevalent infection in Northern Europe. Pseudomembranous colitis was 
mainly observed in Northern Europe (p=0.002) while unproved infections were less prevalent in 
the West (p=0.03). No other differences in the type of infections were observed between groups. 
Nosocomial infections predominated in the whole series (n=273; 52.5%), being more frequent in 
Western and Northern Europe (64% and 56% vs. 38% in the South; p<0.001). Severity of 
infection at diagnosis was also significantly higher in Northern and Western Europe with a higher 
prevalence of severe sepsis/shock (22% and 19% vs. 9% in the South, p<0.001) and ACLF (56% 
and 57% vs. 38% in the South, p<0.001). 
 
Bacteria isolated in the whole series, across European regions, per country and per center 
A total of 284 bacteria were isolated in 264 culture-positive infections (50.8%). Isolation rate 
was significantly higher in Northern and Western Europe (56% each vs. 43.5% in the South; 
p<0.001, Table 1). Bacterial isolation was similar in nosocomial, healthcare-associated (HCA) 
  
and community-acquired (CA) infections (53% vs. 47% vs. 49%; p=0.519). The rate of positive 
cultures was 75% in UTI, 52% in SBP, 45% in SSTI and 43% in pneumonia.  
Supplementary Table 1 shows all bacteria isolated in the whole series, in Northern, Southern and 
Western Europe and per country. Escherichia coli was the most frequently isolated organism 
(35%), followed by Staphylococcus aureus (10.5%), Enterococcus faecalis (10%), Klebsiella 
pneumoniae (7%) and Streptococcus viridans and Enterococcus faecium (5% each).  
Eighty out of the 284 organisms isolated in the study (28.1%) were MDROs. They were isolated 
in 77 infections (14.8% of all infections, 29.2% of culture-positive infections) from 61 patients 
(13.4%). As a whole, ESBL-producing Escherichia coli was the most frequent MDRO reported 
(n=19), followed by VSE (n=15), MRSA (n=12) and ESBL-producing Klebsiella pneumoniae (n=9) 
(Table 2). The total number of isolated MDROs was significantly higher in infections occurring in 
Northern and Western Europe [14 (19%) and 46 (19%) vs. 20 (9.7%); p<0.001]. Prevalence of 
MDROs also differed significantly among countries ranging from 0% in Switzerland, Czech 
Republic and Denmark, 7% in Spain, 19.6% in Italy, 21% in UK, 25% in Ireland and 34% in 
France (p <0.001) [Table 2].  
Type of isolated MDROs also differed among countries (Table 2) and European regions (Table 2, 
Suppl Figure 1). ESBL and Amp-C producing Enterobacteriaceae were more frequent in France 
(18%), followed by Italy (13%), UK and Netherlands (12% each), Austria (3.8%), Belgium (3.4%) 
and Spain (3%). VSE predominated in France and Austria (8% each) and MRSA in infections 
occurring in The Netherlands (6%), UK and Ireland (5% each). Infections by XDR bacteria were 
infrequent and heterogeneously distributed. Carbapenem-resistant Klebsiella pneumoniae was 
reported in 2 patients (<1%), 1 from UK and 1 from Germany while carbapenem-resistant 
Pseudomonas aeruginosa was reported in 4 cases, 2 in Southern Europe (0.8%; 1 in Italy, 1 in 
Spain) and 2 in Western Europe (0.8%; France). VRE was also infrequent (n=3) and diagnosed in 
Northern (2.8%; 1 in UK and 1 in Ireland) and Western Europe (0.4%; 1 in Germany). No 
  
statistically significant differences were observed when comparing the type of MDROs isolated in 
the different European regions. No PDR bacteria was reported.  
Suppl Table 2 and Figure 1 show the MDR bacteria isolated in the different centers in the 
Canonic series. Nineteen centers (70%) reported infections caused by MDROs. Remarkable 
differences were observed in the prevalence and type of MDR strains among hospitals. Frankfurt 
(41%), Clichy (39%), Villejuif (30%) and London (King’s College, 27%) showed the highest 
prevalence of MDROs while no resistant strains were reported in Aarhus, Hvidovre, Bern, Graz, 
Ghent, Madrid (Ramon y Cajal) and Prague. No culture-positive infections were reported in 
Vienna. ESBL-E. coli predominated in Clichy, Frankfurt, Barcelona (St. Pau), Padua, London 
(King’s College) and Leuven and ESBL-Klebsiella pneumoniae in London (UC) and Hamburg. 
Prevalence of ESBL/Amp-C ß-lactamase-producing Enterobacteriaceae (panel A) and of MRSA 
(panel B) observed in the different centres participating in the Canonic Study is shown in Figure 
2. A heterogeneous distribution of MDROs was observed among different centres, even in those 
located in the same geographical region and city. 
 
Infections caused by MDROs 
Table 3 shows the prevalence, type, clinical and epidemiological characteristics of bacterial 
infections caused by MDROs in the whole series and in the different European regions. 
Prevalence of MDR bacterial infections was 14.8% if all infections are considered (13.4% if 
analysis is restricted to only one infection per patient) and 29.2% in culture-positive episodes. 
Prevalence of MDROs was significantly higher in Northern and Western Europe (all infections: 
18.1% and 19.3%; culture-positive infections: 32.5% and 34.6%) than in Southern Europe (8.7% 
and 20%, respectively). MDROs were more frequently isolated in bacteremia (28.6%), pneumonia 
(23.5%), and UTI (20.7%) in the whole series, although differences were not statistically 
significant. The rate of isolation of MDROs was not significantly different among specific 
  
infections in the different European regions. MDR bacteria were also more frequently isolated in 
ICU (23.8% vs. 12.2%; p=0.005) and in nosocomial infections (21.3% vs. 8.3% and 6.6% in CA 
and HCA infections, respectively; p<0.001). Finally, MDROs were more prevalent in infections 
causing severe sepsis/shock (30.3% vs. 12.2%, p<0.001) or ACLF (20.5% vs. 9.4%, p<0.001). 
 
Type and efficacy of first line antibiotic strategies 
Two main factors influenced first line antibiotic schemes: the site of acquisition of infection and 
severity (Suppl. Table 3). Classical antibiotic strategies were used frequently in CA infections as 
first line therapy in Western (80.5%) and Southern Europe (74.6%) but not in the North (33.3). In 
contrast, nosocomial episodes were mainly treated with strategies covering MDROs in the 3 
European regions analyzed (71.1%, 63.6% and 60%, in Northern, Southern and Western Europe, 
respectively). Both strategies were similarly used for the empirical treatment of HCA infections, 
except for Northern Europe, where MDR covering strategies were again predominantly used. 
Remarkably, patients with severe sepsis/shock received more frequently broad-spectrum 
antibiotics covering MDROs in the whole series and in Northern, Southern and Western Europe 
(73.3%, 62.5%, and 67.5%, respectively). However, antibiotic prescription differed among 
European regions in patients with sepsis. MDR covering strategies were used more frequently in 
septic patients in the North (93.3%) and classical strategies in the South (72%). 
The efficacy of classical and MDR empirical antibiotic strategies is shown in Table 4. In the whole 
series, empirical MDR covering strategies were more effective (higher infection resolution rate or 
higher adequacy to the microbiological susceptibility) than empiric classical schemes in 
nosocomial infections (81.7% vs. 68%, respectively, p=0.01). A trend towards statistical 
significance was also observed in severe sepsis/shock (81.3% vs. 60.9%, p=0.06) and in 
infectious episodes with or without sepsis (84.7% vs. 76.7%, p=0.06). This higher efficacy of 
MDR covering strategies was observed in nosocomial episodes reported in the 3 European 
  
regions, although differences were only statistically significant in Western Europe. Inadequacy of 
first line antibiotic strategies increased 28-d mortality in both AD (33.3% vs. 7.7%; p<0.001) and 
ACLF patients (50% vs. 25.8%, p=0.002)(Suppl. Table 4, Figure 3).  
Suppl. Table 5 shows the type of empirical antibiotic strategies prescribed in the centers showing 
a high prevalence of MDR bacterial infections (>15%). Initial schemes differed markedly among 
centers as well as resolution rate. 
 
Impact of antibiotic resistance on clinical outcome  
Table 5a shows the clinical outcome of infections caused by MDROs in comparison to that 
observed in infections caused by susceptible bacteria or with no microbiological isolation in the 
whole series and across European regions. Resolution of infection was significantly lower in 
episodes caused by MDROs (71.4% vs. 87.6%, p<0.001). Infections caused by MDR strains 
showed higher prevalence of severe sepsis/shock (31.9% vs. 12.2%, p<0.001), ACLF (67.5% vs. 
45.6%, p<0.001) and 28-d mortality (35.1% vs. 18.1%, p= p<0.001). The negative impact on 
clinical outcome of antibiotic resistance was confirmed across the different European regions, 
although we only observed significant differences on short-term mortality in Northern and 
Western Europe, probably as result of the higher baseline severity of infections in these regions. 
Clinical impact of antibiotic resistance was also evaluated considering the adequacy of initial 
antibiotic strategies (Table 5b). Resolution rate of infections with no isolation or caused by 
susceptible bacteria was significantly higher (90.8% vs. 71.4%; p<0.001) and 28-d mortality 
significantly lower (14.9% vs. 41.1%; p<0.001) if initial antibiotic strategies were adequate. 
Adequacy of empirical antibiotic strategies was also associated with higher resolution rate (82.2% 
vs. 58.1%; p=0.02) and a trend towards lower 28-d mortality (26.7% vs. 45.2%, p=0.09) in 
infections caused by MDROs. 
 
  
 
 
Risk factors for MDR bacterial infection 
Table 6 and Suppl. Table 6 show the risk factors associated with the development of infections 
caused by MDROs in the univariate and multivariate analysis in the whole series and in culture-
positive infections. Nosocomial infection (OR: 2.74; 95% CI: 1.45-5.19; p=0.002), ICU admission 
(OR: 2.09; 95% CI: 1.11-3.96; p=0.02) and recent hospitalization (OR: 1.93; 95% CI: 1.04-3.58; 
p=0.038) were identified as independent predictors of MDR infection in the whole series. 
Mechanical ventilation (OR: 2.90; 95% CI: 1.35-6.23; p=0.006) was the only factor independently 
associated with MDR infection in nosocomial episodes. No independent predictors of MDR 
infection were identified for CA and HCA infections. Similar results were obtained when the 
analysis was restricted to culture-positive infections.  
 
SECOND SERIES 
Clinical characteristics and epidemiology of bacterial infections  
A total of 284 patients (32.2%) developed 392 bacterial infections. Prevalence of infection was 
significantly higher in Eastern (45.4%) and Southern Europe (39.4%) than in the West (18.5%; 
p<0.0001; Suppl. Table 7). UTI (n=104), SBP (n=50), pneumonia (n=43), bacteremia (n= 38) and 
SSTI (n=24) were the most frequent proved infections in this series. CA infections predominated 
in the whole population (n=189; 53%) and in the different European regions. Severity of infection 
at diagnosis was similar among the different European regions. Prevalence of MDR bacterial 
infections was 23.3% if all infections are considered and 37.9% in culture-positive episodes. No 
significant differences in the prevalence of MDR bacterial infections were observed among 
European regions when all infections were considered. In contrast, MDR strains were more 
  
frequently isolated in culture-positive infections developed in Eastern and Southern Europe 
(Suppl. Table 7). 
Suppl. Table 8 shows the type of MDROs isolated in the second series. Ninety-six MDR strains 
were isolated in 83 MDR bacterial infections. As a whole, ESBL-producing Escherichia coli 
continued to be the most frequent MDRO reported (n=25), followed by VSE (n=15), ESBL-
producing Klebsiella pneumoniae (n=14), carbapenem-resistant Enterobacteriaceae (n=8), and 
MRSA and VRE (n=5 each). When comparing the type of MDROs isolated in the different 
European regions only ESBL-producing Klebsiella pneumoniae was significantly more frequent in 
Eastern Europe (11.8% vs. 2.3% and 1.2% in Southern and Western Europe; p=0.002). No PDR 
bacteria was reported. Figure 4 shows the prevalence and type of MDR bacteria isolated in the 
different centers. Fifteen centers (79%) from 8 countries (89%) reported infections caused by 
MDROs. Remarkable differences were observed in the prevalence and type of MDR strains 
among hospitals. 
 
  
 
DISCUSSION  
The current investigation reports for the first time the epidemiology of MDR bacterial infections in 
decompensated cirrhosis and ACLF across Europe. The study analyzes information prospectively 
recorded in two series and includes 739 patients with bacterial infection enrolled in 32 centers 
from 16 countries. From a geographically point of view, the study constitutes the broadest 
epidemiological assessment of bacterial infections ever performed in cirrhosis. Our investigation 
confirms that MDR bacterial infections constitute a global and growing healthcare problem in 
hepatology. MDR were reported in 70% of the liver units and in 9 of the 12 countries participating 
in the Canonic study, figures that increased to almost 80% of hospitals and 8 out of 9 countries in 
the more recent series. Prevalence of MDR bacterial infections varied markedly among European 
regions being higher in Northern and Western Europe in the Canonic series and in Eastern and 
Southern Europe in the second series. This discrepancy is probably related to differences in the 
epidemiological characteristics of infections between series. The pattern of antibiotic resistance 
was highly heterogeneous, with marked differences in the type of MDROs among countries and 
centers in the two series analyzed. 
The overall prevalence of MDR bacterial infections in the whole Canonic cohort of culture-positive 
infections was 29.2% (14.8% if all infections are considered). This figure is similar to that reported 
in some single-center investigations performed in European countries. Studies published so far 
report a prevalence of MDROs in culture-positive infections ranging from 8% in Turkey, 19-21% in 
Greece, 14-24% in Sweden-Germany and 21-31% in Spain to 31% in France and 27-46% in 
Italy.6,12,13,15,20,26-31 It is important to remark that there were marked differences in the prevalence 
of MDROs among countries in the first series. MDROs isolation rate varied from 0% in 
Switzerland, Czech Republic and Denmark and 7% in Spain to 20% in Italy, 21% in UK, 25% in 
Ireland and 34% in France. Belgium, Germany, The Netherlands and Austria showed 
intermediate rates of MDROs. Prevalence of MDR bacterial infections increased to 38% in 
  
culture-positive episodes in the second series, with also important differences among regions. 
This increase in the rate of MDR bacterial infections, almost 10% in less than 8 years, underlines 
the growing clinical relevance of antibiotic resistance in decompensated cirrhosis and ACLF. 
Differences in the prevalence of MDROs were also observed among the participant centers in the 
two series, even among those located in the same geographical region or city. Frankfurt, Clichy, 
Villejuif and King’s College of London in the Canonic series and Roma, Bologna, Bern and Turin 
in the second series showed the highest prevalence of MDROs meanwhile other centers reported 
no resistant strains or intermediate MDR rates. The low number of infections recorded in centers 
reporting no MDROs in the first and second series (44 and 37 infections in total, respectively) 
probably explain the absence of MDROs isolation. On the other hand, both series extended for a 
short time period (7 and 11 months), feature that could have limited our capacity to precisely 
evaluate the real prevalence of MDROs in the different countries and centers. Both factors could 
also explain the discrepancies observed in the prevalence of MDROs in the same center between 
the two series (Bern, Leiden, Munich) and between our study and other investigations (i.e. Spain 
and Italy).6,12,21 
In the Canonic series, ESBL-producing Enterobacteriaceae was the MDRO more frequently 
isolated in the study followed by VSE and MRSA. However, the type of resistant strain 
significantly differed across countries and centers. ESBL and Amp-C producing 
Enterobacteriaceae were more frequently isolated in France, Italy, UK and The Netherlands; VSE 
predominated in France and Austria and MRSA in infections occurring in The Netherlands, UK 
and Ireland. ESBL-producing Enterobacteriaceae continued to be the most frequent MDRO 
reported in the 2017-2018 series, but marked differences were newly observed in the type of 
resistant bacteria among regions and centers. This finding underlines the importance of having 
surveillance programs at a local level aimed to investigate the prevalence and epidemiological 
  
pattern of MDROs at each hospital. Global epidemiological data are informative but are not 
applicable to specific centres.32 
Infections by XDR bacteria were infrequent and heterogeneously distributed in the Canonic 
series. Carbapenem-resistant Klebsiella pneumoniae, carbapenem-resistant Pseudomonas 
aeruginosa and VRE were reported sporadically in different European regions in this first series. 
Infections by these difficult to treat bacteria continued to be infrequent in the more recent series 
but we observed the emergence of carbapenem-resistant Eschericha coli as XDR bacteria and a 
small increase in the rate of infections caused by VRE. No PDR bacteria were reported in both 
series. Our results suggest therefore that although XDR bacteria constitute a growing and 
extremely dangerous problem in cirrhosis, global infection rates are far from those reported in 
single center studies (from 3% to 14%).12 , 32. 
MDR bacteria were more frequently isolated in the ICU and in nosocomial episodes. MDR 
bacterial infections were more severe (higher rate of severe sepsis/shock and/or ACLF at 
diagnosis) and associated to lower resolution rate and higher mortality at 28-d, especially if 
treated with inadequate empirical antibiotic strategies. Our results, therefore, confirm previous 
studies in decompensated cirrhosis showing that antibiotic resistance is associated to poor 
prognosis and high short-term mortality.10,13,17,20-22 This poor prognosis of infections caused by 
MDROs has also been reported in patients with solid or hematological malignancies and in critical 
care in the general population.33-35 
Nosocomial origin of infection, ICU admission and recent hospitalization within the previous 3 
months were the only independent risk factors for MDR bacterial infections identified in the whole 
Canonic cohort, finding that underlines the key relevance of hospitalization in determining the 
epidemiological risk of antibiotic resistance in the cirrhotic population. Instrumentation, exposure 
to broad-spectrum antibiotics and possibly in-hospital colonization by MDR bacteria could 
account for this finding. In contrast to previous studies, long-term norfloxacin prophylaxis10 was 
  
not identified as risk factors of MDR in the current series. The low number of patients on long-
term quinolone prophylaxis in our study (n=7) prevented us from evaluating adequately this 
potential risk factor. Rate of antibiotic resistance was low in HCA infections in the Canonic series 
but similar to that observed in nosocomial episodes in the more recent series, feature probably 
related to differences in the epidemiological characteristics between countries and centers. 
Mechanical ventilation, a parameter reflecting both organ support and high degree of 
instrumentation, was the only factor independently associated with MDR infection in nosocomial 
episodes. Regretfully, we were unable to identify risk factors for MDR infections developing within 
the first 48h of hospitalization. 
The current study also describes for the first time the type and efficacy of empirical antibiotic 
strategies used across Europe. Classical antibiotics, those based on third-generation 
cephalosporins and quinolones, were mainly used in CA infections while schemes covering 
MDROs were prescribed more frequently in nosocomial episodes and in severe sepsis/shock. As 
a whole, MDR covering strategies were more effective than classical schemes, especially in 
nosocomial infections. Importantly, inadequacy of first line antibiotic strategies had a negative 
impact on short-term survival, both in AD and in ACLF patients, feature also observed when the 
analysis was restricted to MDR bacterial infections. Our findings support therefore the current 
recommendations on empirical antibiotic strategies in decompensated cirrhosis. Broad schemes 
covering all potential pathogens should be empirically used in the nosocomial setting and in 
severe sepsis/shock and should be followed by rapid de-escalation strategies to avoid a further 
spread of antibiotic resistance.1,9,36,37 First line antibiotic strategies should be decided locally 
together with the infectious disease specialists and should consider the specific epidemiological 
pattern of antibiotic resistance, feature highly heterogeneous according to the results of the 
current investigation. Two recent studies demonstrate the efficacy of adapting the empirical 
antibiotic strategies to the local pattern of resistance.38,39 
  
Our investigation confirms the increasing prevalence and negative impact of MDR bacterial 
infections in cirrhosis in the majority of the European centers participating in the study. This 
observation demands the urgent evaluation of new strategies aimed at preventing the spread of 
antibiotic resistance in the cirrhotic population. Clinical impact and cost/effectiveness of measures 
such as epidemiological surveillance (regular assessment of potential carriers of MDROs through 
rectal and nasal swabs during hospitalization)40,41, rapid microbiological tests (micro-arrays or 
multiplex PCR techniques capable of detecting gene targets specific of MDROs and MALDI-TOF 
MS),42,43 and antibiotic stewardship programs deserve further evaluation. 9,44,45 
In conclusion, our study demonstrates that MDR bacterial infections constitute a global and 
growing healthcare problem in decompensated cirrhosis and ACLF across all Europe. The 
pattern of antibiotic resistance was highly heterogeneous, with marked differences in the type of 
MDROs among countries and centers. Antibiotic resistance was associated to poor prognosis 
and to failure of first line antibiotic strategies based on third-generation cephalosporins or 
quinolones.  
  
  
 FIGURE LEGENDS 
Figure 1 
Type and overall rate of MDROs isolation in the different European centres participating in the 
Canonic study. Different colours represent different MDR bacteria. The colour of the circle is 
determined by the most prevalent MDROs in each centre and its size correlates with the overall 
prevalence of MDROs at this centre, also shown in brackets. Marked differences in the type and 
prevalence of MDROs were observed among centres.  
 
Figure 2 
Rate of infections caused by ESBL and Amp-C producing Enterobacteriaceae (Panel A) and 
MRSA (Panel B) across the different European centres participating in the Canonic study. Marked 
differences were observed among centres. 
 
Figure 3 
Probability of death at day 28 in infected patients receiving adequate or inadequate empirical 
antibiotic strategies in the whole series (Panel A), in patients with acute decompensation (AD; 
Panel B) and in ACLF patients (Panel C) in the Canonic study. Inadequacy of empirical strategies 
significantly increased the probability of death in the three populations. 
 
Figure 4  
Type and overall rate of MDROs isolation in the different European centres participating in the 
second study (2017-2018). Different colours represent different MDR bacteria. The colour of the 
circle is determined by the most prevalent MDROs in each centre and its size correlates with the 
  
overall prevalence of MDROs at this centre, also shown in brackets. Marked differences in the 
type and prevalence of MDROs were observed among centres.  
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Table 1. Prevalence, type, epidemiological characteristics and baseline severity of bacterial infections across 
Europe (Canonic series) 
 
 Total Northern 
Europe 
Southern 
Europe 
Western Europe p 
Prevalence (infected patients/%) 455(39.7)* 66(39.1) 178(40.6) 208(38.9) 0.846 
Overall infections (number of infections/%) 520* 72(13.9) 207(40.0) 238(46.1)  
Overall culture-positive infections (number of infections/%) 264(50.8)* 40(55.6) 90(43.5) 133(55.9) <0.001 
Type of infection (n /%)    
 
  
SBP 130(25.0) 13(18.1) 52(25.1) 62(26.1) 0.375 
UTI   111(21.4) 10(13.9) 51(24.6) 50(21.0) 0.156 
Skin and soft tissue infections  44(8.5) 10(13.9) 15(7.3) 19(8.0) 0.203 
Pneumonia 85(16.4) 16(22.2) 23(11.1) 46(19.3) 0.024 
Unproved infections 67(12.9) 11(15.3) 35(16.9) 21(8.8) 0.033 
Secondary bacterial peritonitis 21(4.0) 6(8.3) 8(3.9) 7(2.9) 0.125 
Spontaneous or secondary bacteremia 28(5.4) 2(2.8) 12(5.8) 14(5.9) 0.566 
Pseudomembranous colitis 4(0.8) 3(4.2) 1(0.5) 0(0.0) 0.002 
Other 30(5.8) 1(1.4) 10(4.8) 19(8.0) 0.082 
      
Site of admission at infection dx (n /%)     <0.001 
Emergency department 189(43.1) 16(24.6) 105(64.0) 68(32.9)  
Ward 170(38.7) 32(49.2) 47(28.7) 88(42.5)  
ICU 80(18.2) 17(26.2) 12(7.3) 51(24.6)  
Site of acquisition (n /%)     <0.001 
Community-acquired 156(30.0) 20(27.8) 90(43.5) 45(18.9) 
 
HCA 91(17.5) 12(16.7) 38(18.4) 40(16.8)  
Nosocomial 273(52.5) 40(55.6) 79(38.2) 153(64.3)  
  
Severity at infection diagnosis (n/%)     <0.001 
No sepsis  295(62.4) 36(53.7) 140(73.3) 116(54.7)  
Sepsis  106(22.4) 16(23.9) 34(17.8) 56(26.4)  
Severe sepsis or septic shock 72(15.2) 15(22.4) 17(8.9) 40(18.9)  
ACLF at infection diagnosis (n /%)     <0.001 
No 266(51.1) 32(44.4) 129(62.3) 103(43.3) 
 
Yes 254(48.9) 40(55.6) 78(37.7) 135(56.7)  
SBP: spontaneous bacterial peritonitis; UTI: urinary tract infections; ICU: intensive care unit; HCA: healthcare-
associated; ACLF: acute on chronic liver failure.  
*Three infections occurring in 3 patients in Czech Republic (Eastern Europe) were not considered in the comparative 
analysis among European regions  
Data are shown as number of infections and percentage. SAS (version 9.4; SAS Institute Inc.; Cary, NC) statistical 
package. 
 
 
 
  
Table 2. Rate and type of MDROs isolated in the whole series, in Northern, Southern and Western Europe and by country (Canonic series) 
  
Northern 
Europe 
N=72 
 
Southern 
Europe 
N=207 
 
Western 
Europe 
N=238 
 
P 
 
 
Austria 
N=26 
 
Belgium 
N=58 
 
Germany 
N=93 
 
Ireland 
N=20 
 
UK 
N=42 
 
The 
Netherlands
N=7 
 
Italy 
N=46 
 
Spain 
N=161 
 
 
France 
N=50 
 
All 
infections* 
N=520 
Total isolated MDR (n/%) 14(19.4) 20(9.7) 46(19.3) 0.012 5(19.1) 7(12.1) 15(16.3) 5(25.0) 9(21.4) 2(11.8) 9(19.6) 11(6.8) 17(34.0) 80(15.4) 
Total isolated MDR in culture-positive infections (n/%) 14(35.0) 20(22.2) 46(34.6) 0.302 5(31.3) 7(21.9) 15(34.1) 5(55.6) 9(36.0) 2(28.6) 9(52.9) 11(15.1) 17(50.0) 80(30.3) 
Total isolated MDR GNB (n/%) 8(11.1) 14(6.8) 28(11.8) 0.186 2(7.6) 3(5.2) 11(12.0) 2(10.0) 6(14.3) 1(5.9) 7(15.2) 7(4.3) 11(22.0) 50(9.6) 
ESBL-producing Escherichia coli 2(2.8) 6(2.9) 11(4.6) 0.571 1(3.8) 2(3.4) 3(3.2) - 2(4.8) - 4(8.7) 2(1.2) 5(10.0) 19(3.7) 
ESBL-producing Klebsiella pneumonia 3(4.2) 4(1.9) 2(0.8) 0.161 - - 1(1.1) - 3(7.1) - 2(4.3) 2(1.2) 1(2.0) 9(1.7) 
ESBL-producing Klebsiella oxytoca - - 1(0.4) 1.000 - - 1(1.1) - - - - - - 1(0.2) 
Amp-C producing Enterobacter spp. 1(1.4) 1(0.5) 4(1.7) 0.491 - - 1(1.1) 1(5.0) - - - 1(0.6) 3(6.0) 6(1.2) 
ESBL-producing Serratia spp - - 1(0.4) 1.000 - - - - - 1(5.9) - - - 1(0.2) 
Carbapenem-resistant Klebsiella pneumonia 1(1.4) - 1(0.4) 0.411 - - 1(1.1) - 1(2.4) - - - - 2(0.4) 
Carbapenem-resistant Pseudomonas aeruginosa - 2(1.0) 2(0.8) 1.000 - - - - - - 1(2.2) 1(0.6) 2(4.0) 4(0.8) 
Stenotrophomonas maltophilia 1(1.4) - 2(0.8) 0.548 1(3.8) - 1(1.1) 1(5.0) - - - - - 3(0.6) 
Burkholderia cepacia. - - 1(0.4) 1.000 - - 1(1.1) - - - - - - 1(0.2) 
Acinetobacter baumanii - 1(0.5) 3(1.3) 0.348 - 1(1.7) 2(2.2) - - - - 1(0.6) - 4(0.8) 
  
Total isolated multiresistant GPC (n/%) 6(8.3) 6(2.9) 18(7.6) 0.068 3(11.5) 4(6.9) 4(4.3) 3(15.0) 3(7.1) 1(5.9) 2(4.3) 4(2.5) 6(12.0) 30(5.8) 
MR Staphylococcus aureus (MRSA) 3(4.2) 1(0.5) 8(3.4) 0.071 1(3.8) 2(3.4) 2(2.2) 1(5.0) 2(4.8) 1(5.9) - 1(0.6) 2(4.0) 12(2.3) 
Vancomycin-susceptible Enterococcus faecium (VSE) 1(1.4) 5(2.4) 9(3.8) 0.493 2(7.7) 2(3.4) 1(1.1) 1(5.0) - - 2(4.3) 3(1.9) 4(8.0) 15(2.9) 
Vancomycin-resistant enterococci (VRE) 2(2.8) - 1(0.4) 0.136 - - 1(1.1) 1(5.0) 1(2.4) - - - - 3(0.6) 
 
* Seventeen infections reported in Switzerland (n=4), Czech Republic (n=3) and Denmark (n=10) had no isolation of MDR bacteria. Data are presented as number of bacteria and percentage 
 
 
 
 
  
Table 3 Prevalence, type, epidemiological characteristics and severity of bacterial infections caused by MDROs 
in the whole series and in Northern, Southern and Western Europe* (Canonic series) 
 
   Total Northern 
Europe 
Southern 
Europe 
Western  
Europe 
P 
Prevalence 61/455(13.4) 12/66(18.2) 12/178(6.7) 37/208(17.8) 0.005 
Overall infections (n MDRi*/total infections/%) 77/520(14.8) 13/72(18.1) 18/207(8.7) 46/238(19.3) 0.005 
Culture-positive infections (n MDRi*/total infections/%) 77/264(29.2) 13/40(32.5) 18/90(20.0) 46/133(34.6) 0.056 
Type of infection (n MDRi*/total infections/%)      
Spontaneous bacterial peritonitis 18/130(13.9) 4/13(30.8) 4/52(7.7) 10/62(16.1) 0.084 
Urinary tract infection 23/111(20.7) 1/10(10.0) 9/51(17.7) 13/50(26.0) 0.398 
Skin and soft tissue infections  5/44(11.4) 2/10(20.0) 1/15(6.7) 2/19(10.5) 0.582 
Pneumonia  20/85(23.5) 4/16(25.0) 2/23(8.7) 14/46(30.4) 0.132 
Secondary bacterial peritonitis 3/21(14.3) 1/6(16.7) 0/8(0.0) 2/7(28.6) 0.283 
Spontaneous or secondary bacteremia 8/28(28.6) 1/2(50.0) 2/12(16.7) 5/14(35.7) 0.442 
Other 0/30(0.0) 0/1(0.0) 0/10(0.0) 0/19(0.0) - 
     
Site of admission at dx (n MDRi*/total infections/%)     
Emergency department  20/189(10.6) 2/16(12.5) 7/105(6.7) 11/68(16.2) 0.135 
Ward 22/170(12.9) 6/32(18.8) 3/47(6.4) 13/88(14.8) 0.228 
ICU 19/80(23.8) 4/17(23.5) 2/12(16.7) 13/51(25.5) 0.811 
Site of acquisition (n MDRi*/total infections/%)      
Community-acquired 13/156(8.3) 3/20(15.0) 5/90(5.6) 5/45(11.1) 0.284 
HCA 6/91(6.6) 0/12(0.0) 1/38(2.6) 5/40(12.5) 0.133 
Nosocomial 58/273(21.3) 10/40(25.0) 12/79(15.2) 36/153(23.5) 0.281 
Severity at infection diagnosis** (n MDRi*/total infections/%)     
No sepsis 37/295(12.5) 6/36(16.7) 10/140(7.1) 21/116(18.1) 0.024 
Sepsis 12/106(11.3) 0/16(0.0) 3/34(8.8) 9/56(16.1) 0.173 
Severe sepsis or septic shock 23/72(30.3) 6/15(40.0) 4/17(23.5) 13/40(32.5) 0.604 
ACLF at infection diagnosis (n MDRi*/total infections/%)      
No 25/266(9.4) 2/32(6.3) 9/129(7.0) 14/103(13.6) 0.186 
Yes 52/254(20.5) 11/40(27.5) 9/78(11.5) 32/135(23.7) 0.053 
SBP: spontaneous bacterial peritonitis; UTI: urinary tract infections; ICU: intensive care unit; HCA: healthcare-
associated; MDRi: MDR infections; ACLF: acute on chronic liver failure 
  
*Data on severity of infection were not available in 54 episodes. Data are presented as number of infections and 
percentage. SAS (version 9.4; SAS Institute Inc.; Cary, NC) statistical package.
  
Table 4. Efficacy of first line antibiotic strategies in the whole series and among European regions (Canonic series)## 
 
 
 
 Whole series  Northern Europe  Southern Europe  Western Europe  
 Classical* MDR 
coverage** 
P Classical* MDR 
coverage** 
P Classical* MDR 
coverage** 
P Classical* MDR 
coverage** 
P 
Total 165/218(75.7) 201/237(54.9) 0.014 15/21(71.4) 38/46(82.6) 0.296 73/88(83.0) 66/77(85.7) 0.627 76/108(70.4) 95/112(84.8) 0.010 
Site of acquision (n/%)            
CA or HCA*** 99/121(81.8) 67/73(91.8) 0.056 8/10(80.0) 18/19(94.7) 0.216 53/60(88.3) 24/28(85.7) 0.729 37/50(74.0) 24/25(96.0) 0.021 
Nosocomial 66/97(68.0) 134/164(81.7) 0.012 7/11(63.6) 20/27(74.1) 0.520 20/28(71.4) 42/49(85.7) 0.128 39/58(67.2) 71/87(81.6) 0.048 
Severity of infection (n/%)            
No sepsis / sepsis only 138/180(76.7) 144/170(84.7) 0.057 11/15(73.3) 26/33(78.8) 0.677 66/79(83.5) 53/60(88.3) 0.426 60/85(70.6) 63/75(84.0) 0.045 
Severe sepsis or shock 14/23(60.9) 39/48(81.3) 0.065 2/4(50.0) 10/11(90.9) 0.080 4/6(66.7) 7/10(70.0) 0.889 8/13(61.5) 22/27(81.5) 0.173 
#Resolution of infection without further escalation/bacterial susceptibility to initial antibiotics in culture positive infections 
## Data were not available in 76 infections. Data are presented as number of infections and percentage. SAS (version 9.4; SAS Institute Inc.; Cary, NC) statistical package. 
* One to third generation cephalosporins, amoxicillin-clavulanic acid, quinolones 
  
** Piperacillin-tazobactam or carbapenem±glycopeptide/linezolid/daptomycin  
***CA: community-acquired; HCA: healthcare-associated
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Table 5a. Clinical outcome of infections according to the antibiotic resistant profile of the responsible 
bacteria (Canonic series) 
 
   
Total 
N=520 
No isolation/ susceptible 
bacteria 
N=443 
Multiresistant bacteria* 
N=77 
p-value 
Overall Infections (n)     
Resolution (n/%) 445(85.6) 390(87.6) 55(71.4) <0.001 
ACLF 254(48.9) 202(45.6) 52(67.5) <0.001 
Severe sepsis or septic shock 72(15.2) 49(12.2) 23(31.9) <0.001 
Mortality at 28 days 107(20.6) 80(18.1) 27(35.1) <0.001 
Mortality Tx-free at 28 days 107(21.8) 80(19.2) 27(37.0) <0.001 
North Europe (n) N=72 N=59 N=13  
Resolution (n/%) 59(81.9) 52(88.1) 7(53.9) 0.004 
ACLF 40(55.6) 29(49.2) 11(84.6) 0.020 
Severe sepsis or septic shock 15(22.4) 9(16.4) 6(50.0) 0.014 
Mortality at 28 days 21(29.2) 13(22.0) 8(61.5) 0.005 
Mortality Tx-free at 28 days 21(31.8) 13(24.1) 8(66.7) 0.004 
South Europe (n) N=207 N=189 N=18  
Resolution (n/%) 184(88.9) 171(90.5) 13(72.2) 0.019 
ACLF 78(37.7) 69(36.5) 9(50.0) 0.259 
Severe sepsis or septic shock 17(8.9) 13(7.5) 4(23.5) 0.081 
Mortality at 28 days 34(16.4) 30(15.9) 4(22.2) 0.487 
Mortality Tx-free at 28 days 34(17.2) 30(16.6) 4(23.5) 0.467 
Western Europe (n) N=238 N=192 N=46  
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Resolution (n/%) 199(83.6) 164(85.4) 35(76.1) 0.125 
ACLF 135(56.7) 103(53.7) 32(69.6) 0.050 
Severe sepsis or septic shock 40(18.9) 27(16.0) 13(30.2) 0.098 
Mortality at 28 days 52(21.9) 37(19.3) 15(32.6) 0.049 
Mortality Tx-free at 28 days 52(23.4) 37(20.8) 15(34.1) 0.062 
 
Data are presented as number of infections and percentage. SAS (version 9.4; SAS Institute Inc.; Cary, NC) statistical 
package. 
 
 
 
 
 
 
 
 
 
 
Table 5b. Clinical outcome of infections according to the antibiotic resistant profile of the responsible 
bacteria and the adequacy of empirical antibiotic therapy (Canonic series) 
 
   
Total 
N=520 
No isolation/ susceptible bacteria 
 MR bacteria* 
 
 
   Initial antibiotic therapy   Initial antibiotic therapy  
  
Total 
N=443 
Inadequacy 
N=56 
Adequacy 
N=335 
p-value Total 
N=77 
Inadequacy 
N=31 
Adequacy 
N=45 
p-value 
Overall Infections (n)          
Resolution (n/%) 445(85.6) 390(87.6) 40(71.4) 304(90.8) <0.001 55(71.4) 18(58.1) 37(82.2) 0.021 
ACLF 254(48.9) 202(45.6) 34(60.7) 158(47.2) 0.061 52(67.5) 24(77.4) 27(60.0) 0.112 
Severe sepsis or septic shock 72(15.2) 49(12.2) 9(16.7) 39(12.8) 0.637 23(31.9) 14(46.7) 20(48.8) 0.984 
Mortality at 28 days 107(20.6) 80(18.1) 23(41.1) 50(14.9) <0.001 27(35.1) 14(45.2) 12(26.7) 0.095 
Mortality Tx-free at 28 days 107(21.8) 80(19.2) 23(42.6) 50(16.2) <0.001 27(37.0) 14(46.7) 12(28.6) 0.102 
 
 
ACLF: acute on chronic liver failure 
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#Resolution of infection without further escalation/bacterial susceptibility to initial antibiotics in culture positive infections. 
Data are presented as number of infections and percentage. SAS (version 9.4; SAS Institute Inc.; Cary, NC) statistical 
package. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Risk factors for the development of infections by multiresistant bacteria in the univariate and 
multivariate analysis (Canonic series) 
 
    
  
No multiresistant 
isolation  
(n=443) 
Multiresistant 
bacteria 
(n=77)  
p No MR/MR 
OR (CI 95%)** 
p 
Whole infections      
Nosocomial infection (%) 215(48.5) 58(75.3) <0.001 2.74(1.45-5.19) 0.002 
Health-care associated infection (%) 85(19.2) 6(7.8) <0.001 - - 
Recent hospitalization* (%) 198(45.3) 48(63.2) 0.004 1.93(1.04-3.58) 0.038 
Recent use of β-lactams* (%) 173(42.6) 32(47.1) 0.493 - - 
Long-term norfloxacin prophylaxis (%) 5(1.6) 2(3.0) 0.427 - - 
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ICU admission (%) 61(15.6) 21(27.3) 0.003 2.09(1.11-3.96) 0.023 
Mechanical ventilation (%) 96(31.1) 34(54.0) <0.001 - - 
Hepatic encephalopathy at inclusion (%) 199(45.0) 29(37.7) 0.230 - - 
MELD score (%) 21 ± 8 23 ± 8 0.063 - - 
ACLF 202(45.6) 52(67.5) <0.001 - - 
Second infection 42(9.5) 16(20.8) 0.003 - - 
Diabetes mellitus (%) 87(20.0) 23(31.5) 0.027 - - 
Culture-positive infections (n=187) (n=77)     
Nosocomial infection (%) 87(46.5) 58(75.3) <0.001 3.04(1.52-6.10) 0.002 
Health-care associated infection (%) 37(19.8) 6(7.8) <0.001 - - 
Recent hospitalization* (%) 79(42.7) 48(63.2) 0.002 2.12(1.07-4.20) 0.032 
Recent use of β-lactams* (%) 84(47.2) 32(47.1) 0.985 - - 
Long-term norfloxacin prophylaxis (%) 3(2.1) 2(3.0) 0.682 - - 
ICU admission (%) 21(12.9) 21(27.3) 0.015 2.56(1.20-5.49) 0.016 
Mechanical ventilation (%) 41(29.3) 34(54.0) <0.001 - - 
Hepatic encephalopathy at inclusion (%) 88(47.1) 29(37.7) 0.162 - - 
MELD score (%) 22 ± 8 23 ± 8 0.167 - - 
ACLF 84(44.9) 52(67.5) <0.001 - - 
Second infection 20(10.7) 16(20.8) 0.030 - - 
Diabetes mellitus (%) 36(19.7) 23(31.5) 0.042 - - 
 
ICU: intensive care unit; MELD: model for end stage liver disease; ACLF: acute on chronic liver failure. 
Data are presented as mean±SD or number of infections and percentage. SAS (version 9.4; SAS Institute Inc.; Cary, NC) 
statistical package. 
*: within the previous 3 months.  
**Variables showing a p value <0.1 were introduced in the model 
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How antibiotic resistance develops?
1. Few bacteria are 
resistant
2. Susceptible 
bacteria are killed  
by antibiotics
3. Resistant strains 
grow and spread 
over
Immune
dysfunction
Microbiota
alterations
Clinical
factors: 
Liver
failure, 
ascites, 
bleeding
Genetic
factors
Barrier
failure
Factors favouring bacterial infections in cirrhosis
Resistance to third-generation cephalosporins
in cirrhosis: single centre data 
Prevalence and type of resistant bacteria across European hospitals
How to prevent the spread of antibiotic resistance?
12 European countries, 27 centers
455 infected patients, 264 culture-positive 
infections
29% caused by MDROs
9 European countries, 19 centers
284 infected patients, 219 culture-positive
infections
38% caused by MDROs
2017-20182011
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HIGHLIGHTS 
 
 
1. MDR bacterial infections constitute a prevalent, growing and complex healthcare problem in 
decompensated cirrhosis and ACLF across all European regions. Prevalence increased from 
29% to 38% in culture-positive infections from 2011 to 2017-2018. 
2. Prevalence and type of resistant organisms differ markedly among centers. 
3. Antibiotic resistance negatively impact prognosis. It is associated to lower resolution rate of 
infections, higher incidence of septic shock and ACLF and higher mortality and to failure of 
antibiotic strategies based on third-generation cephalosporins or quinolones. 
4. Nosocomial infection, ICU admission and recent hospitalization are independent risk factors of 
MDR infection. 
5. Strategies aimed at preventing the spread of antibiotic resistance in cirrhosis should be urgently 
evaluated. 
 
